We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Intellia Therapeutics Inc | NASDAQ:NTLA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.89 | 3.42% | 26.90 | 26.88 | 26.91 | 27.1099 | 25.92 | 26.36 | 778,655 | 17:52:36 |
From Jul 2019 to Jul 2024
Details of the upcoming presentations are as follows:
Monday, November 7th 25th Annual Credit Suisse Healthcare Conference, 2016Location: Scottsdale, ArizonaPresentation Time: 11:30 AM MST
Thursday, November 17th Jefferies 2016 London Healthcare ConferenceLocation: London, EnglandPresentation Time: 3:20 PM GMT
Individuals may access the presentations for each conference via live webcast on the Intellia website at www.intelliatx.com under "Events & Presentations" in the "Investor Relations" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 857-706-1071 jenn.smoter@intelliatx.com Investor Contacts: John Graziano Trout Group +1 646-378-2942 jgraziano@troutgroup.com Chad Rubin Trout Group +1 646-378-2947 crubin@troutgroup.com
1 Year Intellia Therapeutics Chart |
1 Month Intellia Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
